<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221230056989N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-30</date_registration>
      <primary_sponsor>University of social welfare and rehabilitation sciences</primary_sponsor>
      <public_title>Effects of percutaneous auricular vagus nerve stimulation  in chronic widespread myofascial pain syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Effects of percutaneous auricular vagus nerve stimulation  in chronic widespread myofascial low back and cervical pain syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>68</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67714</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are divided into two intervention groups (vagus nerve stimulation) and sham group (placebo vagus nerve stimulation) by block randomization. 34 patients are in the intervention group and 34 patients are in the placebo group. 17 blocks are created and there are 4 patients in each block. (2 patients are in the intervention group and 2 patients are in the sham group). The size of the blocks is equal. Election by lots is used between the blocks and people are randomly placed in the blocks based on this election. This method aims to balance the number of samples allocated to each group.
People take out the cards that have a random sequence and the letters A (intervention group) and B (placebo group) are written on them from the box (the cards are inside the envelopes, the contents of the envelopes are not clear).In this way, the assigned group of that patient is determined. In order to maintain a random sequence, the envelopes are numbered in the same order. It should be noted that the random sequence of cards and the allocation of patients to treatment groups are not done by one person so that the randomization process is done correctly.
In order to prevent the interference of information, the days of the treatment sessions during the week for each group is determined randomly, Blinding description: Patients are randomly divided into two groups. intervention groups: vagus nerve stimulation and sham group (placebo vagus nerve stimulation). Electrical stimulation is performed in both groups. In the intervention group, electrical stimulation is performed at the distribution site of the vagus nerve (concha and simba conca area of ​​the ear), but in the placebo group, stimulation is applied at the earlobe, which is not the distribution site of the vagus nerve. Therefore, in this way, patients do not know that they are belong to which group. In order to prevent the interference of information, the days of  treatment sessions during the week for each groups is determined randomly (even or odd days).</study_design>
      <phase>N/A</phase>
      <hc_freetext>Chronic Widespread Myofascial Low Back and Cervical Pain Syndrome.</hc_freetext>
      <i_freetext>Intervention group: The intervention group is assigned 10 sessions of percutaneous auricular vagus nerve stimulation (biphasic rectangular with 250 microseconds pulse and  25 Hz) is applied for 30 minutes in conchae and cymba conchae area of ear (site of distribution of the auricular vagus nerve). Shame group: 10 sessions stimulation in earlobe (biphasic rectangular with 250 microseconds pulse and  25 Hz) which is not the site of distribution of the vagus nerve..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
A code is considered for each patient and the data related to variables, primary and secondary outcomes for each patient are entered based on that code and these data can be shared.

When:
Up to one year after the publication of the study results

To whom:
Our data will be available to researchers in academic and scientific institutions

Conditions:
If it is necessary to perform more statistical analyses on the data or to obtain results other than ours, the data will be accessible.

Where to obtain:
Mahboobeh Abdolalizadeh, Gmail: mahabd55@gmail.com, Tel: 00989133409234

How to obtain:
The applicant submits his/her request via email or phone, and the information and data will be provided to them within 2 weeks after the call.

Comments:
The applicant should comply confidentiality rules.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahboobeh Abdolalizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alley 11, Vesal St, Jomhoori Eslami Blvd, Kerman, Iran</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7618471911</zip>
        <telephone>+98 34 3265 3297</telephone>
        <email>mahabd55@gmail.com</email>
        <affiliation>University of social welfare and rehabilitation sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahboobeh Abdolalizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alley 11, Vesal St, Jomhoori Eslami Blvd, Kerman, Iran</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7618471911</zip>
        <telephone>+98 34 3265 3297</telephone>
        <email>mahabd55@gmail.com</email>
        <affiliation>University of social welfare and rehabilitation sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients in age 25 to 55 years
Body mass index less than 30 kg/m2
Having the criteria of lumbar and neck myofascial syndromes based on the criteria provided by Travell and Simon in the muscles of the back and neck
the patient have pain for at least 3 months.
The presence of at least 3 trigger points in the muscles of the back and neck, where one of these two areas involves the muscles bilaterally (by using an algometer, as well as by touch)
Intensity of pain of at least 3 out of 10 on the Visual Analog Scale (VAS)
Patients whose Wide Spread Pain Index (WPI) is equal to or greater than 7</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>55 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Neurological diseases
Metabolic and endocrine diseases
Systemic diseases such as lupus, scleroderma
Infectious diseases
Inflammatory diseases
Thyroid diseases
History of malignancy
Diabetes
Pregnancy
Menopause
Use of painkillers in the last 24 hours
Long-term use of corticosteroids
Drug addiction
Cognitive and psychotic diseases
Myopathies
Cardiovascular diseases
Taking drugs that affect the autonomic system, such as cholinergic and anticholinergic drugs, alpha and beta blockers, antipsychotics</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G89.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chronic pain syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The intervention group is assigned 10 sessions of percutaneous auricular vagus nerve stimulation (biphasic rectangular with 250 microseconds pulse and  25 Hz) is applied for 30 minutes in conchae and cymba conchae area of ear (site of distribution of the auricular vagus nerve). Shame group: 10 sessions stimulation in earlobe (biphasic rectangular with 250 microseconds pulse and  25 Hz) which is not the site of distribution of the vagus nerve.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Heart Rate Variability (HRV). Timepoint: Before and after 10 sessions. Method of measurement: PowerLab  data  acquisition  system.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Low Back Pain Disability. Timepoint: Before and after 10 sessions. Method of measurement: Oswestry Low Back Pain Disability (ODI).</sec_outcome>
      <sec_outcome>Low Back Pain Diability. Timepoint: Before and after 10 sessions. Method of measurement: Roland-Morris Disability Questionnaire (RMQ).</sec_outcome>
      <sec_outcome>Neck Disability. Timepoint: Before and after 10 sessions. Method of measurement: Neck Disability Index (NDI).</sec_outcome>
      <sec_outcome>Kinesiophobia. Timepoint: Before and after 10 sessions. Method of measurement: Tampa Scale of Kinesiophobia (TSK).</sec_outcome>
      <sec_outcome>Anxiety. Timepoint: Before and after 10 sessions. Method of measurement: Beck Anxiety Inventory (BAI).</sec_outcome>
      <sec_outcome>Heart Rate Variability. Timepoint: Before and after 10 sessions. Method of measurement: PowerLab  data  acquisition  system.</sec_outcome>
      <sec_outcome>Pain Pressure Threshold (PPT). Timepoint: before and after 10 sessions. Method of measurement: algometer.</sec_outcome>
      <sec_outcome>Pain. Timepoint: before and after 10 sessions. Method of measurement: Visual Analog Scale (VAS).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>University of social welfare and rehabilitation sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-01-18</approval_date>
        <contact_name>Research ethics committees of University of Social Welfare and Rehabilitation Sciences</contact_name>
        <contact_address>kodakyar Ave., daneshjo Blvd.,Evin, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran Post code: : 1985713871 Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
